Alaska Chapter of the American College of Cardiology

Latest in Cardiology from ACC.org

• Atenolol Associated With Lower MACE Risk After MI Than Bisoprolol
  Among patients without recorded heart failure (HF), starting atenolol after a myocardial infarction (MI) was associated with a lower two-year risk of major adverse cardiovascular events (MACE), but not all-cause mortality, compared with bisoprolol, according to an observational cohort study published Sept. 22 in NEJM Evidence.
• ACC/AHA Joint Guideline Committee Reaffirms Perioperative Guideline
  After evaluating new evidence published over the last two years on perioperative cardiovascular management of patients following noncardiac surgery, the ACC/AHA Joint Committee on Clinical Practice Guidelines has determined that the most recent perioperative guideline published in 2024 “remains valid and current.” Read the full guideline published in JACC.
• ACCEL Lite: PRESC1SE-MI: Efficacy of the ESC 0/1-hour Pathway
  In this episode, Jeroen J. Bax PhD, MD, FACC and Jasper Boeddinghaus, MD discuss “PRESC1SE-MI: Safety and efficacy of the ESC 0/1-hour Pathway”.
• Statins For the Prevention of Anthracycline-Induced Cardiotoxicity: Contextualizing Guideline Recommendations For Clinical Practice
  Anthracycline-induced cardiotoxicity is a major contributor to long-term cardiovascular (CV) outcomes in survivors of cancer. Up to 20% of patients exposed to anthracyclines develop irreversible cardiomyopathy through mechanisms leading to cardiomyocyte death.
• PAD Series Spotlights Current Burden, Future Challenges
  A three-part series published Sept. 22 in The Lancet underscores the growing global impact of peripheral artery disease (PAD) and reinforces the need for earlier diagnosis, improved treatment and better access to care.